Podcasts

OncLive On Air^® is a podcast from OncLive^® that provides oncology professionals with the resources and information they need to provide the best patient care. Segments cover every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. New episodes with exclusive interviews with leading oncology experts are released on Mondays and Thursdays.

Early Biomarker Testing Optimizes Tepotinib Use in NSCLC With MET Exon 14 Skipping Mutations: With Stephen Liu, MD

October 1st 2025

Dr Liu discusses the 2 VISION trial of tepotinib for NSCLC harboring MET exon 14 skipping alterations, as well as the importance of biomarker testing.

Expanding JAK Inhibitor Use Offers Increased Treatment Options for Cytopenic Myelofibrosis: With Andrew Kuykendall, MD

September 29th 2025

Andrew Kuykendall, MD, provides an overview of the myelofibrosis treatment paradigm.

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

September 26th 2025

Early CAR T-Cell Therapy Data Highlight Therapeutic Potential and Emerging Challenges in GI Cancers: With Kohei Shitara, MD

September 25th 2025

Kohei Shitara, MD, discusses optimizing treatment strategies and addressing unmet needs in resectable gastric and gastroesophageal junction cancers.

The Evolving Role of Noncovalent BTK Inhibition Informs CLL Treatment Selection: With Asad Dean, MD

September 24th 2025

Dean discusses the role of BTK inhibitors in the management of CLL and the importance of molecular profiling for treatment rechallenge decisions.

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

September 23rd 2025

Establishing the Rationale for ADC and ICI Combinations in TNBC

September 22nd 2025

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

September 19th 2025

Zidesamtinib Is Associated With CNS Activity and Low Rates of Neurologic AEs in Pretreated ROS1+ NSCLC: With Alexander Drilon, MD

September 18th 2025

Dr Drilon discusses the efficacy data and implications of the ARROS-1 trial, highlighted the mechanism of action of zidesamtinib in ROS1-positive NSCLC.

Patient Characteristics and Disease Factors Guide the Use of Dostarlimab in Recurrent Endometrial Cancer: With Dana M. Chase, MD

September 17th 2025

Dana M. Chase, MD, discusses the management of recurrent endometrial cancer, emphasizing the importance of biomarker profiles and previous therapies.

Cohort Analysis Shows Importance of Early-Onset CRC Awareness and Investigation: With Evelyn Y. Wong, MD

September 15th 2025

Dr Wong discusses the growing challenge of early-onset colorectal cancer and the insights from a recent cohort analysis conducted in Singapore.

Patient Characteristics and Care Team Collaboration Influence Treatment Decision-Making in CLL: With John N. Allan, MD; and Melissa Rubianes

September 11th 2025

Allan and Rubianes discuss factors that influence treatment decision-making for patients with chronic lymphocytic leukemia.

Recent FDA Approvals and Ongoing Research Expand Treatment Options for Soft Tissue Sarcoma: With Samantha A. Armstrong, MD; and Karine Tawagi, MD

September 8th 2025

Drs Armstrong and Tawagi discuss key aspects of soft tissue sarcoma management.

Clinical Trial and Real-World Data With NALIRIFOX Shape the Future of Pancreatic Cancer Care: With Tara E. Seery, MD; Paul E. Oberstein, MD; and Priyadarshini Pathak, MBBS

September 4th 2025

Drs Seery, Oberstein, and Pathak discuss data from the NAPOLI 3 trial of NALIRIFOX vs nab-paclitaxel and gemcitabine in treatment-naive pancreatic cancer.

Advances in ctDNA Testing Guide Clinical Decision-Making in GI Cancer Management: With Scott Kopetz, MD, PhD, FACP

September 3rd 2025

Dr Kopetz discusses the value of ctDNA assays, trials that have shown prognostic implications with this type of assay, and the future of ctDNA research.

Safety and Quality-of-Life Considerations Shape ADT Use in Prostate Cancer: With Tanya B. Dorff, MD

September 2nd 2025

Dr Dorff discusses the role of ADT in prostate cancer management, how this class has evolved, and the use of relugolix across treatment settings.

FDA Approval Insights: Dordaviprone in H3K27M-Mutated Diffuse Midline Glioma: With Patrick Y. Wen, MD

September 1st 2025

Dr Wen discussed the significance of the FDA approval of dordaviprone for patients at least 1 year of age with H3K27M-mutated diffuse midline glioma.

Refining First-Line Immunotherapy Strategies in Hepatocellular Carcinoma: With Masatoshi Kudo, MD, PhD

August 21st 2025

Masatoshi Kudo, MD, discusses the evolving treatment landscape in HCC and how recent comparative analyses are helping refine the use of first-line immunotherapy-based regimens.

Exploring NCCN Guideline Updates and Advancing Immunotherapy Strategies in Nasopharyngeal Carcinoma: With Neal S. Akhave, MD

August 14th 2025

Neal S. Akhave, MD, discusses the addition of toripalimab to the NCCN guidelines for nasopharyngeal carcinoma.

Frank’s Path to Advancing Hematology Through Innovation and Discovery: With Girindra Raval, MD; and David A. Frank, MD, PhD, FACP

August 13th 2025

Girindra Raval, MD, and David A. Frank, MD, PhD, FACP, discuss Frank’s journey, through his undergraduate studies at MIT, and completion of an MD/PhD program at Yale University.